The Crypto That’s Making Wall Street Sweat

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth

Neil Josephson Biography and Net Worth

Insider of Zymeworks

Dr. Josephson joined Zymeworks in April 2019 and currently serves as our interim Chief Medical Officer and Senior Vice President, Clinical Research. Prior to joining Zymeworks he was a Vice President in Clinical Development at Seattle Genetics where he worked on multiple early and late-stage programs from 2013-2019, including leading the first line approval of ADCETRIS^® in Hodgkin Lymphoma. From 2002-2013 Dr. Josephson was a full-time faculty member of the Division of Hematology at the University of Washington and the Puget Sound Blood Center, serving as an Associate Professor of Medicine and the Director of Hemophilia Care Program. He completed fellowship training in Hematology and Oncology at the University of Washington and holds an M.D. degree from Columbia University and an A.B. in biology from Dartmouth College.

What is Neil Josephson's net worth?: The estimated net worth of Neil Josephson is at least $222,370.11 as of November 10th, 2022. Dr. Josephson owns 14,449 shares of Zymeworks stock worth more than $222,370 as of November 15th. This net worth estimate does not reflect any other assets that Dr. Josephson may own. Learn More about Neil Josephson's net worth.
How do I contact Neil Josephson?: The corporate mailing address for Dr. Josephson and other Zymeworks executives is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. Zymeworks can also be reached via phone at (302) 274-8744 and via email at [email protected]. Learn More on Neil Josephson's contact information.
Has Neil Josephson been buying or selling shares of Zymeworks?: Neil Josephson has not been actively trading shares of Zymeworks over the course of the past ninety days. Most recently, Neil Josephson sold 2,475 shares of the business's stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $8.10, for a transaction totalling $20,047.50. Following the completion of the sale, the insider now directly owns 14,449 shares of the company's stock, valued at $117,036.90. Learn More on Neil Josephson's trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Neil Josephson (Insider), Neil Klompas (CFO), Kathryn O'Driscoll (Insider), James Priour (Insider), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last twelve months, insiders at the sold shares 7 times. They sold a total of 40,583 shares worth more than $436,263.55. The most recent insider tranaction occured on January, 8th when CFO Christopher Astle sold 1,431 shares worth more than $16,055.82. Insiders at Zymeworks own 1.9% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 1/8/2024.

Neil Josephson Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/10/2022	Sell	2,475	$8.10	$20,047.50	14,449
1/7/2022	Buy	5,000	$14.28	$71,400.00

Neil Josephson Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Today's Range

Now: $15.39

$15.00

$16.24

50 Day Range

MA: $13.51

$11.70

$17.40

2 Week Range

Now: $15.39

$7.54

$17.70

Volume

627,915 shs

Average Volume

625,659 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16